Evidence map›Paper›PMID 40175450›Full record

ArticleScientific reports2025

Correlation and prognosis analysis of human papillomavirus infection and P16 expression in oral and oropharyngeal squamous cell carcinomas.

Yandie Lin, Zhirui Li, Kai Zhang, Xiaoyue Li, Liwei Shao, Aijun Liu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Circulating tumor HPV DNA versus PET-CT for surveillance in oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Review
  2. Article
  3. Article
  4. Saliva-based molecular diagnostics in oral squamous cell carcinoma (OSCC): a non-invasive frontier in oncology.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yandie Lin *Department of Pathology, The Seventh Medical Center of PLA General Hospital, Beijinɡ, 100070, China.
Zhirui Li *Department of Stomatology, The First Medical Center of PLA General Hospital, Beijinɡ, 100853, China.
Kai ZhangDepartment of Stomatology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233000, China.
Xiaoyue LiDepartment of Pathology, The Seventh Medical Center of PLA General Hospital, Beijinɡ, 100070, China.
Liwei ShaoDepartment of Pathology, The Seventh Medical Center of PLA General Hospital, Beijinɡ, 100070, China.
Aijun LiuDepartment of Pathology, The Seventh Medical Center of PLA General Hospital, Beijinɡ, 100070, China. aliu301@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of HPV-related oral squamous cell carcinomas (OSCC)and oropharyngeal squamous cell carcinomas (OPSCC) has increased significantly in recent years, but the role of HPV and P16 in OSCC and OPSCC remains controversial. Here, we evaluate the prevalence and prognostic significance of HPV-DNA, HPV E6E7 and P16 protein expression in OSCC and OPSCC patients. Additionally, we explore the correlation between P16 protein expression and HPV infection in these cases. The results show that the HPV DNA infection rate was significantly higher in OPSCC at 16.7% compared to 3.6% in OSCC (P = 0.002), HPV DNA positive cases were more prevalent in poorly- differentiated cases (P = 0.009). HPV E6E7 positive cases (10.4%) were only detected in OPSCC. P16 (+++) was observed in 6 of 48 OPSCC cases (12.5%) and in 1 of 140 OSCC cases (0.7%). P16 (+++) was significantly higher in OPSCC than in OSCC (P = 0.003). However, in OPSCC, Using P16 (+++) as a marker for HPV DNA infection yielded a sensitivity of 62.5%, Kappa coefficient between HPV DNA and P16 (+++) was 0.67 (P <0.0001). HPV DNA infection and P16 (+++) were not linked to prognosis (DFS: P = 0.35, P = 0.51; OS: P = 0.99, P = 0.96), Moreover, In OSCC, Age, T, N, and clinical stages were correlated with prognosis. Our results indicate that P16 (+++) can act as a biomarker for HPV- related high-risk tumors in OPSCC, yet not in OSCC. Besides, Older patients, less favorable T, N, and clinical stages having a worse prognosis in OSCC. In those with OPSCC, only the younger age of patients was associated with a better prognosis.

Indexed as

Carcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16Mouth NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsAdultAgedBiomarkers, TumorDNA, ViralFemaleHumansMaleMiddle AgedPapillomaviridaePrognosisBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16DNA, ViralHPV DNAHPV E6E7OPSCCOSCCP16Prognosis

Identifiers

PMID40175450
PMCPMC11965501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.